Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) upgraded to Overweight by JPMorgan with $11 price target. Promising clinical trials for FAP treatment using REC-4881 show 75% reduction in polyp burden. Potential peak sales over $1 billion with REC-4881. Company generated $400 million in milestone payments from partnerships. RXRX uses AI to accelerate drug development.

Positive clinical trials boost Recursion’s prospects. REC-4881 shows promising results for FAP treatment. Investment company sees potential peak sales over $1 billion. REC-617, a CDK7 inhibitor, also shows early anti-tumor activity in ovarian cancer. Company generated $400 million in milestone payments from partnerships.

JPMorgan upgrades Recursion Pharmaceuticals, Inc. (RXRX) based on promising FAP treatment prospects. REC-4881 shows significant reduction in polyp burden. Potential peak sales over $1 billion with REC-4881. REC-617 also shows early anti-tumor activity in ovarian cancer. Company generated $400 million in milestone payments from partnerships.

Read more at Yahoo Finance: JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects